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Abstract
Background—Genitourinary infections (GUIs) are common among sexually active women. Yet, 
little is known about the risk of birth defects associated with GUIs.
Methods—Using data from the National Birth Defects Prevention Study, a multisite, population-
based, case-control study, we assessed self-reported maternal GUIs in the month before through 
the third month of pregnancy (periconception) from 29,316 birth defect cases and 11,545 
unaffected controls. We calculated odds ratios (ORs) and 95% confidence intervals to estimate the 
risk of 52 major structural birth defects associated with GUIs. We also calculated risk of birth 
defects associated with each type of GUI: urinary tract infection (UTI) and sexually transmitted 
infection (STI).
Results—In our analysis, 10% (n = 2,972) of case and 9% (n = 1,014) of control mothers 
reported a periconceptional GUI. A GUI was significantly associated with 11 of the 52 birth 
defects examined (ORs ranging from 1.19 to 2.26): encephalocele, cataracts, cleft lip, esophageal 
atresia, duodenal atresia/stenosis, small intestinal atresia/stenosis, colonic atresia/stenosis, 
transverse limb deficiency, conoventricular septal defect, atrioventricular septal defect, and 
secundum atrial septal defect. A periconceptional UTI was significantly associated with nine birth 
defects (ORs from 1.21 to 2.48), and periconceptional STI was significantly associated with four 
birth defects (ORs ranging from 1.63 to 3.72).
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Conclusions—While misclassification of GUIs in our analysis is likely, our findings suggest 
GUIs during the periconceptional period may increase the risk for specific birth defects.
Keywords
birth defects; congenital malformations; genitourinary infections; infections; sexually transmitted 
infections; urinary tract infection
1 | INTRODUCTION
Genitourinary infections (GUIs) include both sexually transmitted infections (STIs) and 
urinary tract infections (UTIs). These infections are common among sexually active women 
(Centers for Disease Control and Prevention [CDC], 2017; Sheffield & Cunningham, 2005). 
Several epidemiological studies reported an association between GUIs and gastroschisis, 
(Baer et al., 2015; Draper et al., 2008; Elliott et al., 2009; Feldkamp et al., 2008; Feldkamp 
et al., 2015; Yazdy, Mitchell, & Werler, 2014) including one using data from the National 
Birth Defects Prevention Study ([NBDPS]; Feldkamp et al., 2008). Few studies have 
assessed the association of maternal GUIs with other birth defects and those that have done 
so often present conflicting results. Comparing the existing findings is challenging, because 
studies have different exposure definitions and include different birth defect phenotypes or 
groupings.
Prior analyses of NBDPS data examined the association between specific GUIs and birth 
defects. Analyzing births from 1997 to 2003, Cleves, Malik, Yang, Carter, and Hobbs (2008) 
identified associations between maternal UTIs and two congenital heart defects (CHDs): left 
ventricular outflow tract obstructive defects and atrioventricular septal defects. Carter et al. 
(2011) examined GUIs (defined as STIs, pelvic inflammatory disease [PID], and group B 
streptococcus), finding associations with three birth defects among NBDPS births from 1997 
to 2004: renal agenesis/hypoplasia, cleft lip, and transverse limb deficiency. Both analyses 
were limited by few numbers of exposed mothers and did not explore all birth defects 
collected in the NBDPS. We conducted a detailed analysis of the association between GUIs 
and the risk of major birth defects (excluding gastroschisis) using NBDPS data on births 
from 1997 to 2011. We sought to use the findings to generate hypotheses for future research.
2 | METHODS
The NBDPS was a large, multisite, population-based, case-control study of birth defects that 
included pregnancies with estimated delivery dates from October 1997 through December 
2011 (Reefhuis et al., 2015). Pregnancies affected by one or more of 30 categories of major 
structural birth defects (cases), excluding those attributed to a known chromosomal or 
single-gene abnormality, were ascertained through birth defects surveillance programs in 10 
states (Arkansas, California, Georgia, Iowa, Massachusetts, New Jersey, New York, North 
Carolina, Texas, and Utah). Control infants were live born without major birth defects 
randomly selected from hospital records or birth certificates in the same time period and 
geographic area as the cases. Each study site and the Centers for Disease Control and 
Prevention obtained Institutional Review Board approval for the NBDPS, and participants 
provided informed consent.
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Case inclusion criteria have been described previously (Reefhuis et al., 2015). Briefly, case 
information (abstracted from medical records) was obtained from birth defects surveillance 
programs. Clinical geneticists reviewed each case to determine eligibility and to classify 
cases as having isolated (only one defect), multiple (major birth defects in more than one 
organ system), or complex birth defects (Rasmussen et al., 2003). CHD cases were further 
classified according to a structured protocol that took into account cardiac phenotype, 
complexity, and presence of non-cardiac defects (Botto, Lin, Riehle-Colarusso, Malik, & 
Correa, 2007). Birth defects that were known or strongly suspected to be caused by single-
gene disorder or chromosomal anomaly were excluded from the NBDPS.
Trained interviewers conducted computer-assisted telephone interviews in English or 
Spanish with mothers of case and control infants. Interviews occurred between 6 weeks and 
24 months after the estimated date of delivery. Mothers reported demographics, pregnancy 
history, health conditions, medication use, and other exposures before and during pregnancy. 
Overall, 66.7% of eligible case and 63.7% of eligible control mothers participated in the 
interview. The average time between the estimated delivery date and interview was 11 
months among case mothers and 9 months among control mothers. We considered mothers 
exposed if they reported a GUI at any time in the month before conception through the third 
month of pregnancy (periconceptional period). The first 3 months of pregnancy include the 
critical period in embryonic development associated with most structural birth defects. We 
included the month prior to conception in the exposure window as it is often difficult to 
pinpoint the exact date of conception. Mothers reported GUIs in response to the following 
three questions: (a) “Did you have any of the following illnesses: a kidney, bladder, or 
urinary tract infection?”, (b) “Did you have pelvic inflammatory disease or PID?”, and (c) 
“Did you have any other disease or illnesses that we have not already talked about such as 
infectious diseases including sexually transmitted diseases or chickenpox?”. Two 
investigators (MLF, KEA), blinded to case/control status, reviewed all free-text responses to 
the latter question to identify any mention of a GUI. Mothers were classified into four 
exposure groups: (a) any GUI (either UTI or STI), (b) UTI only (including bladder and 
kidney infections), (c) STI only (including Chlamydia trachomatis, gonorrhea, genital 
herpes, human papillomavirus, syphilis, trichomoniasis, bacterial vaginosis, PID, or mention 
of an unspecified STI), or (d) both a UTI and STI. The unexposed group included infants of 
mothers who did not report a periconceptional GUI.
We excluded 3,168 infants (2,883 cases/285 controls) from analysis (Figure 1). We excluded 
mothers with missing information on GUIs and those reporting pre-gestational diabetes. As 
Feldkamp et al. (2008) published results from NBDPS for the association between maternal 
GUIs and gastroschisis, we excluded infants with isolated gastroschisis from the current 
analysis. Lastly, we excluded mothers of infants with isolated birth defects from case groups 
with ≤ 50 cases. Some birth defects (oral clefts, glaucoma, cataracts, ventricular septal 
defects [VSDs], and pulmonary valve stenosis) were not ascertained by all sites for all years 
of the NBDPS (Rasmussen et al., 2003; Reefhuis et al., 2015); when analyzing these birth 
defects, we excluded cases and controls for the sites and years with incomplete data.
We analyzed second- and third-degree hypospadias (i.e., subcoronal/penile, scrotal, or 
perineal meatal opening) and restricted the control group to males.
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To assess potential confounding, we used chi-square tests to compare characteristics among 
control infants whose mothers reported GUIs and those who did not. We used logistic 
regression to estimate crude odds ratios (cORs) and adjusted odds ratios (aORs) with 95% 
confidence intervals (CI) for any GUI, UTI only, STI only, both UTI and STI, and specific 
STI pathogens and the risk of birth defects. We calculated aORs and 95% CIs for birth 
defects with five or more exposed cases, controlling for the following a priori set of 
covariates: maternal age at delivery (a continuous variable), race/ethnicity (non-Hispanic 
white, Non-Hispanic black, Hispanic, other), education (high school or less, more than high 
school), pre-pregnancy body mass index (BMI; weight in kilograms/height in meters2), 
periconceptional cigarette smoking, folic acid-containing supplement use in the month 
before through the first month of pregnancy, and state of residence at the time of the infant’s 
birth. For birth defects with three or four exposed cases, we calculated cORs and Fisher’s 
exact CIs. We did not calculate estimates for birth defects with fewer than three exposed 
cases. We examined whether the associations between any GUI and birth defects varied by 
maternal age or smoking by evaluating additive interaction. We calculated the relative excess 
risk due to interaction along with the 95% CIs for each birth defect using a logistic 
regression model adjusted for the covariates listed above (Hosmer & Lemeshow, 1992).
We conducted three sub-analyses to determine whether specific changes in the analysis 
would affect the results. To reduce heterogeneity, we restricted the analysis of noncardiac 
defects to isolated cases. Similarly, we restricted the analysis of CHDs to cases with only 
one CHD or a well-recognized combination of defects that are considered a single CHD, 
referred to as “simple isolated” cases. Lastly, as GUIs can cause inflammation that may 
persist longer than the underlying infection and could impact embryonic development, we 
examined the association between reported GUIs and the risk of birth defects in a longer 
exposure window, the 3 months before conception through the third month of pregnancy. For 
each of these, we implemented the change and recalculated all ORs and 95% CIs as 
described above. No adjustment was made for the multiple comparisons performed. We 
conducted analyses in SAS (9.3; SAS Corporation, Cary, NC).
3 | RESULTS
After exclusions, 29,316 case and 11,545 control infants were included in the analysis 
(Figure 1). Overall, 2,972 (10.1%) case and 1,014 (8.8%) control mothers reported a GUI in 
the periconceptional period. By type of GUI, 2,457 (8.4%) case and 836 (7.2%) control 
mothers reported having only a UTI, 428 (1.5%) case and 151 (1.3%) control mothers 
reported having only an STI, and 87 (0.3%) case and 27 (0.2%) control mothers reported 
having both a UTI and STI (Figure 1).
The distributions of selected characteristics stratified by the presence or absence of a GUI 
among control mothers are shown in Table 1. Mothers of control infants who reported a GUI 
differed from those who did not report a GUI in terms of age, race/ethnicity, education, pre-
pregnancy BMI, smoking status, folic acid-containing supplement use, and study center. The 
percentage of mothers reporting a GUI decreased with increasing age, and this pattern was 
consistent across the type of GUI (Supporting Information Figure S1). The proportion of 
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reported GUIs was consistently lower in control mothers compared to case mothers, 
regardless of maternal age or type of GUI.
The percentage of mothers who reported a periconceptional GUI varied slightly across the 
52 birth defects examined, ranging from 5.8% of mothers who reported a GUI for total 
anomalous pulmonary venous return (TAPVR) to 20.7% for colonic atresia/stenosis (Tables 
2 and 3). Any GUI was associated with statistically significant elevated aORs ranging from 
1.19 to 2.26 for 11 of the 52 birth defects were studied: encephalocele, congenital cataracts, 
cleft lip only, esophageal atresia, duodenal atresia/stenosis, small intestinal atresia/stenosis, 
colonic atresia/stenosis, transverse limb deficiency, conoventricular VSD, atrioventricular 
septal defect (AVSD), and secundum atrial septal defect (secundum ASD). UTI only was 
associated with statistically significant elevated aORs ranging from 1.21 to 2.48 for 9 of the 
52 birth defects we examined: congenital cataracts, cleft lip only, duodenal atresia/stenosis, 
small intestinal atresia/steno-sis, colonic atresia/stenosis, conoventricular VSD, AVSD, 
hypoplastic left heart syndrome, and secundum ASD. STI only was associated with 
statistically significant aORs ranging from 1.63 to 3.72 for 4 of 52 birth defects in the study: 
holoprosencephaly, cleft lip, transverse limb deficiency, and Ebstein anomaly. While the 
analysis of mothers reporting both UTI and STI was limited by the small number of exposed 
cases, reporting both periconceptional STI and UTI was associated with statistically 
significant elevated cORs for encephalocele and renal agenesis/hypoplasia.
Among mothers who reported any STI, 434 (84%) case and 148 (83%) control mothers 
provided the specific pathogen; Chlamydia was most common (Table 4). Among the 
mothers who only reported an STI, Chlamydia was associated with statistically significant 
elevated aOR for cleft lip only and statistically significant elevated cOR for conoventricular 
VSD (Table 5). Additionally, we found elevated statistically significant aORs for human 
papillomavirus and transverse limb deficiency and for trichomoniasis and cleft lip with cleft 
palate. In crude analyses, gonorrhea was significantly associated with anotia/microtia.
We examined whether the associations between any GUI and each birth defect differed 
across maternal age and smoking status (data not shown). We did not find patterns that 
suggest additive interaction by either maternal age or smoking status for any of the birth 
defects examined. When we restricted to isolated noncardiac birth defects and simple 
isolated CHDs, the point estimates were similar to the estimates in the main analysis for 
most birth defect phenotypes, with the exception being the estimate for isolated cloacal 
exstrophy which became elevated and statistically significant (Supporting Information Table 
S1). When we expanded the exposure window to include the 3 months before conception 
through the third month of pregnancy, we found point estimates that were similar to our 
main findings (Supporting Information Table S2).
4 | DISCUSSION
We assessed associations between GUIs and 52 birth defects in the NBDPS. Self-reported 
periconceptional GUIs were common, and slightly higher in case mothers compared to 
control mothers. We observed that maternal GUI was significantly associated with increased 
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risk of 11 of the 52 individual birth defects examined, although the magnitude of these 
associations varied.
The published literature on this topic mostly comes from three important epidemiologic 
studies that are large enough to examine GUIs and individual birth defects: the Hungarian 
Case-Control Surveillance of Congenital Abnormalities (HCCSCA) (Acs, Banhidy, Puho, & 
Czeizel, 2008a, 2008b, 2008c; Banhidy, Acs, Puho, & Czeizel, 2006, 2010; Metneki, Puho, 
& Czeizel, 2005; Norgard, Norgaard, Czeizel, Puho, & Sorensen, 2006), the Baltimore-
Washington Infant Study (Ferencz, Loffredo, Correa-Villasenor, & Wilson, 1997; Wilson, 
Loffredo, Correa-Villasenor, & Ferencz, 1998), and the NBDPS (Ailes et al., 2016; Carter et 
al., 2011; Cleves et al., 2008). Comparing the existing findings is challenging (Table 6). 
Variations in exposure definitions (in terms of both the infections and exposure windows 
examined) as well as different outcome measures (individual or combinations of birth 
defects) included in these studies prevent a clear picture from emerging.
Of the 11 birth defects that were significantly associated with maternal GUI, the estimate for 
one birth defect, cleft lip, remained elevated and statistically significant among both 
subgroups of GUIs: mothers who reported UTI only (aOR 1.32) and STI only (aOR 1.63). 
We found the magnitude of the cleft lip estimate was even higher among infants whose 
mothers reported Chlamydia (aOR 2.76). These findings for cleft lip are consistent with two 
earlier NBDPS reports (Table 6), one that explored a sub-group of STIs (Chlamydia, 
gonorrhea, and PID) and another that examined maternal nitrofurantoin use for UTI (Ailes et 
al., 2016; Carter et al., 2011), which is unsurprising given the overlap in study participants. 
The HCCSCA explored maternal UTIs and cleft lip +/− cleft palate (and not cleft lip only) 
in two reports: one found an elevated (OR 1.7), but not statistically significant, association 
with cleft lip +/− palate, while the second observed a significant increased OR for cleft lip +/
− palate as well as posterior cleft palate when compared to non-malformed control infants 
(Banhidy et al., 2006; Metneki et al., 2005). No associations with STIs were identified 
(Metneki et al., 2005).
Our estimates for 7 of the 11 birth defects significantly associated with maternal GUI 
remained elevated and statistically significant when we restricted to infants whose mothers 
reported only a UTI, and UTI only was also associated with an increased risk for hypoplastic 
left heart syndrome. Our findings regarding UTI and congenital cataracts, AVSD, and 
hypoplastic left heart syndrome expand on the previous NBDPS findings (Cleves et al., 
2008; Prakalapakorn, Rasmussen, Lambert, & Honein, 2010). While the HCCSCA explored 
a combined outcome of all CHDs and did not identify any association with UTIs, the 
Baltimore-Washington Infant Study reported an association between UTI and secundum 
ASD (Banhidy et al., 2006; Ferencz et al., 1997; Wilson et al., 1998). The association 
between GUI and conoventricular VSDs has not been previously reported.
Three of the birth defects we observed to be associated with GUI, and more specifically with 
UTI, were related to the gastrointestinal tract: duodenal, small intestinal, and colonic atresia/
stenosis. The previous NBDPS analysis that explored antibiotic use for UTIs observed an 
association with esophageal atresia, but not with other gastrointestinal birth defects (Ailes et 
al., 2016). The HCCSCA did not find any significant associations between UTI and 
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gastrointestinal defects, but a nonsignificant elevated risk of diaphragmatic birth defects 
(congenital diaphragmatic hernia and eventration of the diaphragm) was reported with a 
wide confidence interval (Banhidy et al., 2006).
Among mothers who reported only an STI, we observed significant associations with three 
birth defects: holoprosencephaly, transverse limb deficiency, and Ebstein anomaly. The 
increased risk of holoprosencephaly among mothers who reported only an STI (n = 5) was 
largely driven by three cases exposed to Chlamydia (cOR 5.05 [0.99, 16.0]). This finding 
has not been observed in other studies, although brain anomalies, including 
holoprosencephaly, have been recently associated with other maternal infections including 
Zika virus (Hall, Broussard, Evert, & Canfield, 2017; Honein et al., 2017). The magnitude of 
the significant estimates for transverse limb deficiency increased among mothers who 
reported only an STI (aOR = 2.06), and increased further among those with maternal reports 
of HPV (aOR = 4.78). A previous NBDPS report identified an association with STI, 
however, their STI definition included group B streptococcal infections whereas ours did not 
(Carter et al., 2011). Using NBDPS data, Ailes et al. (2016) also observed elevated but not 
significant associations between women who used trimethoprim-sulfamethoxazole for UTI 
treatment and the risk of transverse limb deficiency in their offspring. Lastly, Ebstein 
anomaly was significantly associated with mothers reporting only an STI, but we were 
unable to explore associations by specific STI pathogens given the small number of exposed 
case mothers. While no other estimate for CHDs reached statistical significance among 
mothers who reported only an STI, there were elevated crude ORs for STIs and several 
CHDs, including truncus arteriosus, conoventricular VSDs, atrioventricular VSDs, and 
secundum ASDs. When we restricted to those reporting Chlamydia in the periconceptional 
period, we found a crude significant association between Chlamydia and conoventricular 
VSDs (cOR 5.65); all three conoventricular VSD case mothers who reported an STI reported 
having a chlamydial infection. A previous study identified a significant, but weak, 
association between Chlamydia and the grouped outcome of cyanotic CHDs, which includes 
both Ebstein anomaly and truncus arteriosus (Dong et al., 2016). We were unable to explore 
the relationship between Chlamydia and these two CHDs in more detail, given the lack of 
exposed infants.
Lastly, we found an elevated significant association between GUI and encephalocele, but the 
ORs among those exposed to UTI only and STI only were not elevated or statistically 
significant. Like holoprosencephaly, encephalocele has been with linked with maternal 
infections including Zika virus (Hall et al., 2017; Honein et al., 2017). However, 
encephalocele has not been linked to GUIs in previous studies.
The mechanism by which GUIs act to increase the risk of birth defects is unknown, but 
considerations may include pathogen-mediated damage, the resulting inflammatory 
response, or treatment-related effects. We explored associations by different STI-related 
pathogens, but were hindered by small numbers, resulting in crude estimates with wide 
confidence intervals for several sub-analyses. Additionally, roughly 20% of cases and 
controls did not report a specific pathogen. Another potential mechanism is through a 
maternal inflammatory response to a pathogen. Immune response, and the subsequent 
change in the expression of immune mediators and cytokines in the female reproductive tract 
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after infection, can result in cell death and changes in gene expression, which could impair 
embryonic development. (Robertson, Chin, Femia, & Brown, 2018; Robertson, Chin, 
Schjenken, & Thompson, 2015). If inflammation were an important mediator of birth 
defects, we would expect that a GUI occurring immediately before conception might also 
contribute to increased risk of birth defects given that the inflammation from the infection 
may persist for some time. Finally, GUIs may increase the risk of birth defects through 
medications used to treat GUIs. The treatments for GUIs vary widely, so it seems unlikely 
that one medication is responsible for the range of significant associations observed. Studies 
exploring risk of medications used to treat GUIs, including antibiotics and antiherpetic 
medications, have been inconsistent (Ahrens et al., 2013; Ailes et al., 2016; Andersen et al., 
2013; Hansen et al., 2016; Pasternak & Hviid, 2010; Reiff-Eldridge et al., 2000). We did not 
explore medications in this analysis.
There are many strengths of the NBDPS, including the use of a multisite, population-based 
design that used strict inclusion criteria and classification of cases by clinical geneticists 
(Rasmussen et al., 2003; Reefhuis et al., 2015). Given the large number study population in 
the NBDPS, we were able to evaluate the associations between GUIs and individual birth 
defects. Our analysis of NBDPS data, which included births from 1997 to 2011, benefited 
from the large number of NBDPS participants and included cases and controls analyzed in 
previous NBDPS publications on GUIs. It is important to acknowledge some of the study 
limitations. Misclassification of GUIs, and specific types of GUIs, is likely. Maternal self-
reported infection during pregnancy is subject to both recognition of the infection and recall 
of the infection and its timing. GUIs, particularly STIs, are commonly asymptomatic, 
meaning that a mother may not have symptoms or may be unaware of the infection (Farley, 
Cohen, & Elkins, 2003; Korenromp et al., 2002). Mothers with an asymptomatic infection 
would have been classified as unexposed, potentially leading us to underestimate any true 
associations. The prevalence of GUI in the current analysis (9% of controls and 10% of 
cases) is lower than expected given the reported prevalence of GUIs during pregnancy and 
among women of reproductive age in the literature (CDC, 2017; Sheffield & Cunningham, 
2005). Mothers were interviewed for NBDPS 6 weeks to 24 months after the estimated date 
of delivery; relying on retrospective self-reports of infection makes recall bias a concern. 
Mothers might have misreported or doctors may have misdiagnosed the type of GUI, given 
the similar symptoms. This would not have impacted our main analysis of GUI, but may 
have led to misclassification of specific GUI exposure type. Of the 3,407 mothers in our 
analysis who reported a UTI, 3,221 (95%) reported that the UTI was diagnosed by a doctor. 
While we do not have similar data from the interview for those mothers reporting an STI, we 
would expect a large proportion of positive STI reports to have been based on clinical 
diagnosis.
The number of exposed cases for some birth defects was small, limiting our ability to assess 
risk, especially in subanalyses by type of infection. Additionally, there may be some 
uncontrolled confounding by factors not measured, or residual confounding by measured 
factors. Finally, we conducted many statistical tests, and some of our findings may be due to 
chance. In our main analysis of 52 birth defects, we would expect to observe approximately 
two birth defects with a statistically significantly aOR (52 × 0.05 = 2.6) by chance alone. We 
observed 11 statistically significant associations, and all 11 were elevated aORs. While some 
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of these associations were reported in other studies (e.g., secundum ASD), the majority of 
our significant findings have only been identified in our study and therefore should be 
interpreted cautiously until confirmed in other studies. Probable misclassification and 
underreporting of exposure lead us to be cautious when interpreting our findings. If GUIs do 
increase the risk of birth defects, this highlights a potential opportunity for pre-pregnancy 
prevention, given that GUIs are preventable and treatable.
We sought to identify associations between GUIs and birth defects that may generate future 
hypotheses. Our findings suggest that maternal GUIs in the month before through the third 
month of pregnancy may increase the risk of several different types of birth defects. Future 
research could focus on the larger birth defect phenotypes with more robust results, 
including cleft lip, or on the findings of associations between GUIs and three gastrointestinal 
birth defects (duodenal, small intestinal, and colonic atresia/stenosis). Given the limitations 
of the current analysis, other studies better able to identify infections, and pathogens or 
measure markers of inflammatory response to infections may help to confirm our findings 
and improve our understanding of the underlying mechanisms. Based on the findings of this 
research, women who are planning to or who have recently become pregnant should 
consider talking to their doctors about GUI prevention and treatment.
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FIGURE 1. 
Study population, exclusions, and genitourinary infection status in the month before 
pregnancy through the third month of pregnancy among women in the National Birth 
Defects Prevention Study, 1997–2011
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TABLE 1
Selected characteristics of mothers of controls by reported periconceptional genitourinary infection, National 
Birth Defects Prevention Study, 1997–2011a
Maternal characteristic Genitourinary infection (n = 1,014) n (%)b No genitourinary infection (n = 10,531) n (%)b p valuec
Age (years) <.001
 <24 489 (48.2) 3,251 (30.9)
 25–29 250 (24.7) 2,940 (27.9)
 30 + 275 (27.1) 4,340 (41.2)
Race/ethnicity
 Non-Hispanic white 527 (52.0) 6,160 (58.5) <.001
 Non-Hispanic black 130(12.8) 1,138 (10.8)
 Hispanic 291 (28.7) 2,541 (24.1)
 Other 66 (6.5) 686 (6.5)
Education
 High school or less 503 (51.0) 4,012 (39.0) <.001
 More than high school 484 (49.0) 6,281 (61.0)
Pre-pregnancy BMI
 < 18.5 73 (7.5) 515 (5.1) <.001
 18.5-<25.0 472 (48.5) 5,483 (54.4)
 25-<30 223 (22.9) 2,284 (22.7)
 ≥ 30 205 (21.1) 1,804 (17.9)
Periconceptional smokinga
 Yes 263 (26.6) 1,764(17.1) <.001
 No 726 (73.4) 8,573 (82.9)
Periconceptional alcohol usea
 Yes 375 (38.0) 3,840 (37.3) .655
 No 612 (62.0) 6,462 (62.7)
Gestational diabetes
 Yes 54 (5.5) 474 (4.6) .224
 No 931 (94.5) 9,776 (95.4)
Folic acid-containing supplement used
 Yes 489 (48.8) 5,579 (53.3) .006
 No 514(51.3) 4,883 (46.7)
Study Center
 Arkansas 188 (18.5) 1,248 (11.9) <.001
 California 111 (11.0) 1,131 (10.7)
 Georgia 92 (9.1) 1,148 (10.9)
 Iowa 92 (9.1) 1,171 (11.1)
 Massachusetts 79 (7.8) 1,303 (12.4)
 New Jersey 40 (3.9) 534 (5.1)
 New York 74 (7.3) 886 (8.4)
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Maternal characteristic Genitourinary infection (n = 1,014) n (%)b No genitourinary infection (n = 10,531) n (%)b p valuec
 North Carolina 84 (8.3) 908 (8.6)
 Texas 165 (16.3) 1,199 (11.4)
 Utah 89 (8.8) 1,003 (9.5)
Note. BMI = body mass index (weight in kilograms/height in meters2).
a
Periconceptional defined as the month before through the third month of pregnancy.
b
Totals vary because of missing values.
cChi-square test for difference in the distribution within each covariate.
d
In the month before pregnancy through the first month of pregnancy.
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 c
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 C
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) C
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 C
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; c
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er
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 d
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w
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 a
nt
en
at
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 c
ar
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lo
gb
oo
k,
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ed
ic
al
 re
co
rd
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an
d 
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po
rt;
 1
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ot
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 c
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ot
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at
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-c
on
tro
l s
tu
dy
 o
f l
iv
e 
sin
gl
et
on
 
bi
rth
s i
n 
th
e 
U
ni
te
d 
St
at
es
 d
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 c
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) c
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 c
ya
no
tic
 C
H
D
 a
s 
re
po
rte
d 
on
 th
e 
bi
rth
 
ce
rt
ifi
ca
te
O
R 
(95
% 
CI
) f
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 C
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 =
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at
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D
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 =
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to
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n
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tu
dy
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A
 =
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f C
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or
m
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 =
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x
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al
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 =
 p
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m
m
at
or
y 
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se
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 =
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ar
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ct
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 =
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 p
ap
ill
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s =
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 =
 c
on
ge
ni
ta
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 =
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 =
 c
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t c
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 =
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rio
r c
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 =
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n
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ul
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flo
w
 tr
ac
t o
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tru
ct
io
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de
fe
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pl
as
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 =
 
at
rio
v
en
tr
ic
ul
ar
 se
pt
al
 d
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 c
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